» Articles » PMID: 15966512

A Non-functioning Pituitary Adenoma Initially Mimicking a Microprolactinoma: The Case for Long-term Follow-up of Patients with Mild Hyperprolactinemia?

Overview
Publisher Springer
Specialty Endocrinology
Date 2005 Jun 22
PMID 15966512
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: A correct differential diagnosis of patients with mild hyperprolactinemia is essential to select the most appropriate treatment modality.

Clinical Presentation: A 50-yr-old woman presented to our Department for evaluation of an intra- and suprasellar mass causing progressive visual defect. Mild hyperprolactinemia causing menstrual irregularities was diagnosed in February 1989. In 1992, serum PRL levels ranged from 50 to 70 microg/l and magnetic resonance imaging (MRI) of the hypothalamic-pituitary region showed the presence of a 7 mm microadenoma. Bromocriptine therapy resulted in normalization of PRL levels and menstrual cycle, while a repeat MRI showed no change. Menses stopped in March 1998, when the patient was 46 yr old. Subsequently, the patient complained of worsening headaches and, starting from July 2001, visual disturbances. In March 2002, MRI showed a large pituitary tumor, measuring 40x37x28 mm. In May 2002, the patient was operated through the transsphenoidal approach with apparent total tumor removal. Histological examination confirmed a pituitary adenoma that stained negative for all pituitary hormones. Four months after surgery, the patient reported an improvement of visual function. MRI of the hypothalamic-pituitary region, performed 4, 13 and 25 months after surgery, showed a partially empty sella with no evidence of residual tumor.

Conclusions: This case suggests that, to exclude the alternative diagnosis of nonfunctioning pituitary adenoma or another mass lesion of the hypothalamic-pituitary region, repeat neuroimaging studies during long-term follow-up may be advisable in patients with presumed microprolactinoma who did not show reduction of the tumor during dopaminergic therapy.

Citing Articles

Pituitary tumors in MEN1: do not be misled by borderline elevated prolactin levels.

Livshits A, Kravarusic J, Chuang E, Molitch M Pituitary. 2016; 19(6):601-604.

PMID: 27600151 DOI: 10.1007/s11102-016-0752-z.

References
1.
Losa M, Mortini P, Barzaghi R, Franzin A, Giovanelli M . Endocrine inactive and gonadotroph adenomas: diagnosis and management. J Neurooncol. 2002; 54(2):167-77. DOI: 10.1023/a:1012965617685. View

2.
Ferrari C, PARACCHI A, Mattei A, De Vincentiis S, DALBERTON A, Crosignani P . Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol (Copenh). 1992; 126(6):489-94. DOI: 10.1530/acta.0.1260489. View

3.
Kwekkeboom D, Lamberts S . Long-term treatment with the dopamine agonist CV 205-502 of patients with a clinically non-functioning, gonadotroph, or alpha-subunit secreting pituitary adenoma. Clin Endocrinol (Oxf). 1992; 36(2):171-6. DOI: 10.1111/j.1365-2265.1992.tb00953.x. View

4.
Smith M, Laws Jr E . Magnetic resonance imaging measurements of pituitary stalk compression and deviation in patients with nonprolactin-secreting intrasellar and parasellar tumors: lack of correlation with serum prolactin levels. Neurosurgery. 1994; 34(5):834-9; discussion 839. DOI: 10.1227/00006123-199405000-00007. View

5.
Albuquerque F, Hinton D, WEISS M . Excessively high prolactin level in a patient with a nonprolactin-secreting adenoma. Case report. J Neurosurg. 1998; 89(6):1043-6. DOI: 10.3171/jns.1998.89.6.1043. View